TBCE and Alzheimer disease: Cumulatively, our study of the cytoprotection of the human KCs by the selective nuclear blockade with the NTCI, adds a new and broad translational perspective to the completed Phase two clinical trial of the NTCI (AMTX‐100 CF) for mild to moderate AD (NCT04313400).